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Transforming growth factor ~ (TGF-~) has a growth-inhibitory effect on numerous different cell types of the 
immune system, Including T Iymphocytes. We show In this study that the inhibitory action of TGF-~ on T 
lympbocytes is accompanied by a block of interleukin 2 (lL-2) gene expression wbicb is mediated, at least in 
part, by inhibition of U,2 promoter/enhancer activity. The functional analysis of eis-regulatory (proto-
enbancer) elements of the U,2 enbancer/promoter region sbowed tbat the most TGF-~-responsive element 
maps to its so-called upstream promoter site. The proto-enhancer activity of the upstream promoter site 
element is also inhibited by cyclosporin A. The upstream promoter site DNA barbors two noncanonical, closely 
linked binding sequences for octamer and AP-l-like factors. Botb sites are involved in tbe establishment of IL-2 
enhancer activity. Since the activity of genuine octamer sites but not that of AP-l-binding sites is also impaired 
by TGF-~ and cyclosporln A in EI4 T lymphoma cells, we conclude that both immunosuppressives interfere 
witb tbe activity but not the DNA binding of octamer factors in T Iymphocytes. 
Transforming growth factor J3 (TGF-J3) belongs to a family 
of paracrine factors which are potent inhibitors of cellular 
proliferation (see reference 28 for a review). Numerous 
experimental studies have demonstrated that TGF-J3 has a 
growth-inhibitory action on a variety of lymphoid cells, 
including Band T lymphocytes (12, 19, 20, 43). TGF-f3 is a 
very efficient inhibitor of pre-B-cell maturation, preventing 
expression of the immunoglobulin kappa light-chain locus 
(26, 29). Similarly, TGF-J3 was found to interfere with the 
appearance of membrane immunoglobulin heavy-chain (IgH) 
molecules and the secretion of immunoglobulin proteins in B 
lymphocytes (19). Moreover, TGF-f3 was found to suppress 
the generation of cytotoxic T cells (14), interleukin-2 (IL-2)-
dependent T-cell proliferation, and the upregulation of IL-2 
and transferrin receptors (20). 
A strong but quite different effect of TGF-f3 on the 
synthesis and secretion of numerous cytokines has also been 
detected. In peripheral T lymphocytes, TGF-f3 was able to 
suppress the synthesis of IL-2 and gamma interferon (12, 
39), whereas in similar cell types, the synthesis of tumor 
necrosis factor a and f3 appeared to be resistant to or even 
enhanced by the drug (7, 12). This quite selective effect of 
TGF-J3 on a set of cytokines prompted us to compare the 
action of TGF-f3 with that of the immunosuppressive agent 
cyclosporin A (CsA) at the molecular level. We and others 
have recently shown that CsA and its functional analog 
FK506 suppress early steps ofT-cell activation through their 
interference with a few transcription factors that bind to the 
enhancer of the IL-2 gene (4, 10,35). In particular, CsA and 
FK506 inhibited the activity of NFAT-l, a lymphoid-specific 
factor binding to the two purine boxes of the IL-2 enhancer, 
and the activity of factors that bind to the enhancer's 
upstream promoter site (UPS). We will show here that the 
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latter site is specifically recognized by octamer and AP-l-like 
factors. 
In nonlymphoid cell types, TGF-f3 has been reported to 
exert its negative effect on numerous genes through a variety 
of binding motifs for transcription factors. In several rat cell 
lines, an inhibitory activity of TGF-J3 on the transinlstromel-
ysin promoter has been detected which appeared to be 
mediated through a noncanonical AP-l/Fos binding site (21). 
In other studies, an inhibitory effect of TGF-J3 on the 
synthesis of jun mRNAs that results in suppression of 
AP-l-mediated gene activities has been reported (16,22,25, 
27,46). In other reports, an effect ofTGF-J3 on expression of 
the c-myc gene which seems to be mediated through the 
protein product of the retinoblastoma (Rb) gene has been 
reported (28, 30). A target site for the Rb protein within the 
fos promoter has been identified (36), and a similar site might 
exist within the c-myc promoter (30). 
In this communication, we will show that in T lymphoma 
cells, TGF-f3 inhibits the transcriptional induction of the IL-2 
gene through closely linked non canonical octamer and AP-l 
binding motifs within the UPS of the IL-2 enhancer. TGF-f3 
impairs the activity of octamer factors in T and B lymphoma 
cells, whereas, in contrast to the situation in several other 
cell lines, the activity of AP-l-like factors remains unaffected 
by TGF-f3 in T cells. Moreover, the activity of NF-KB-like 
factors was found to be slightly stimulated in T cells, and, 
contrary to the action of CsA, the activity of NFAT-l was 
marginally inhibited. Since the activity of octamer factors 
was also found to be impaired by CsA in T but not in B 
lymphoma cells, TGF-f3 and CsA differ in their inhibitory 
action on the IL-2 enhancer and octamer factors. 
MATERIALS AND METHODS 
Cell culture and tnnsrection assays. Murine El4 T lym-
phoma cells and human Jurkat T lymphoma cells were grown 
in RPM I medium supplemented with 5% fetal calf serum to 
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a density of about 2 x 105 cells per ml. DNA (20 ~g) from the 
constructs described below (purified by two CsCI density 
gradient centrifugations) was transfected into about 5 x 107 
El4 cells in a final volume of 3.6 ml by the DEAE-dextran 
protocol as described earlier (42). One-fourth of the cells 
were pretreated for 15 h with TGF-~ (2.5 nglml; from porcine 
platelets; H. Biermann GmbH, Bad Nauheim, Germany), 
and one-fourth were treated with CsA (100 nglml), and both 
treatments were followed by induction with 10 ng of 12-0-
tetradecanoyl-phorbol-13-acetate (TPA) per ml-2.5 ~g of 
concanavalin A (ConA) per ml (TP NConA) in the presence 
of inhibitors. Another one-fourth was treated with TP N 
ConA alone, and the remaining one-fourth was used as the 
uninduced control. In cotransfection experiments (see Fig. 
3B), 2.5 ~g of the 5 x UPS chloramphenicol acetyltransferase 
(CAT) reporter construct was transfected into Jurkat cells 
along with 5 ~g of the Oct-2A expression vector pOEV1 + 
(31). After induction, the cells were incubated for 20 h in 
RPMI medium and sonicated, and their CAT values were 
measured after determination of the protein content as 
described before (42). The ratio of induction was calculated 
by dividing the percentage of chloramphenicol acetylation of 
induced cells (or of induced and TGF-~- or CsA-treated 
cells) by the percentage of acetylation of uninduced cells. 
For the determination of luciferase activities (see Fig. 3C), 
cell extracts were prepared and assayed by the standard 
protocol (9). The expression levels were corrected for the 
protein concentration. 
DNA cloning. All re comb in ant DNA work was done by 
standard procedures (38). The construction of the proto-
enhancer constructs 5xUPS, 5xTCEd, and 4xPu-bd , con-
taining multimers of the protein-binding sites of the IL-2 
enhancer in front of the thymidine kinase (tk) promoter of 
CAT vector pBLCATI, has been described before (4, 5, 35, 
42). Construct 5xUPS carries five copies of the UPS, 
spanning nucleotides from positions -64 to -94 of the IL-2 
enhancer (4) (see Fig. 2B); 5 x TCEd carries five copies of the 
KB-like sequence from -191 to -215 (5); and 4 x Pu-bd 
carries four copies of the distal purine box from - 264 to 
-292 (35) (see Fig. 2A). Construct 5xTREcoll contains five 
copies of the human collagenase promoter (2). Construct 
4xOct bears four copies of the 51-bp-Iong DdeI-HinfIfrag-
ment of the murine IgH enhancer (15) cloned in front of the 
tk promoter in pBLCATI. The luciferase reporter constructs 
8 x Oct-Iucif and 8 x Oct-M-Iucif contain eight copies of either 
the octamer consensus sequence ATGCAAAT or the mu-
tated sequence ATGAAAA T, respectively, in front of a 
truncated tk promoter (spanning the promoter sequences up 
to position -38) and the luciferase gene (9). The IgH-E-CAT 
plasmid (a kind gift of I. Berberich), containing the intronic 
enhancer of the murine IgH gene, was constructed by 
inserting the XbaI-E fragment from intron 2 of the IgH gene 
(3) in front of the tk promoter in pBLCATI. The point 
mutation 152C within the TREp and the UPS mutations 
UPSOM' UPSOM' and UPSOTM were introduced into the 
IL-2 wild-type enhancer by using the Amersham site-di-
rected mutagenesis system followed by dideoxy sequencing, 
as recommended by the manufacturer. The following muta-
genic primers were used: 
152C· TREp: (- 142)5' ·CTGATGACTQTCTGGAATTT·3'( -163) 
UP5-rM: (-65)5 '-CACGATGTTTl'ACATATTACACgTATTT-3'(-92) 
UPSOM: (-60)5' -GGTGTCACGATGTTQQACATA-3'( - SO) 
UPSOTM : (-69)5' -ATGTTTl'A.QQgATTACACgTAT-3' (-90) 
Isolation of nuclear proteins and EMSAs. Crude nuclear 
proteins of lymphoid cells were prepared by the procedure of 
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FIG. 1. TGF-p and CsA inhibit the appearance of authentic 
cytoplasmic IL-2 RNA upon induction of El4 T lymphoma cells. (A) 
Autoradiograph of an Sp6 RNA protection experiment. A 644-
nucleotide-long antisense Sp6 riboprobe of construct pGemII-E4R 
(44), shown in panel B, was hybridized to cytoplasmic RNA 
extracted from non induced E14 cells (lane 1) or from El4 cells 
induced for 4 h with TPNConA (lane 2). Lanes 3 and 4, El4 cells 
treated for 12 h with 2.5 ng of TGF-p (lane 3) or 100 ng of CsA (lane 
4) before induction. After RNase treatment, the protected RNA 
probe was fractionated on a 5% urea-polyacrylamide gel along with 
HpaII-digested pBR322 DNA as size markers (lane M). Note the 
appearance of a band of about 373 nucleotides, (nt), corresponding 
in size to correct IL-2 RNA transcripts (IL-2 RNA). The hybridiza-
tion signal with an actin probe is also indicated. 
Schreiber et al. (41). For the electrophoretic mobility shift 
assays (EMSAs), about 4 ~g of protein was incubated in a 
final volume of 15 ~l with 5,000 cpm (equivalent to about 0.2 
ng) for 20 min on ice along with 2 ~g of poly(dI . dC) by 
published procedures (40). After the incubation, the samples 
were fractionated in native 5% polyacrylamide gels at 200 
V /15 cm at room temperature. The gels were dried and 
exposed at -70°C. In the competition assays, a 25- to 
lOO-fold excess (as specified in the figure legends) of unla-
beled double-stranded oligonucleotide probes was added to 
the incubation mixture 5 min prior to the addition of the 
radioactively labeled probe. 
RNA analysis. Whole RNA from El4 cells was extracted 
by the guanidinium thiocyanate procedure and centrifuged 
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FIG. 2. Structure of the IL-2 enhancer and the sequence of its UPS. (A) IL-2 enhancer. The positions of protein-binding sites are indicated 
by boxes. The solid boxes indicate the CsA- and FK506-sensitive proto-enhancer elements, the two purine boxes (Pu-bd and Pu-bp), and the 
UPS (4). The hatched boxes indicate the CsA- and FK506-resistant (or distinctly less sensitive) proto-enhancer elements, namely the distal 
T-cell element TeEd (a KB-Iike binding site [5]) and the proximal TPA-responsive element TREp (a weak binding site of AP-I [32]). The TCEp 
(which appeared to be inactive in pro to-enhancer tests [4]) and the upstream sites US-I and US-2/3 (the function of which is unknown) are 
indicated by open boxes; the two TATA boxes are indicated by stippled boxes. The binding of factors was determined in either DNase I 
footprint protection or EMSA experiments (4, 5, 35, 42) with purified factors (AP-I, AP-3, and NF-KB) or protein extracts from EI4 T 
lymphoma cells. The vertical arrows below the enhancer show either the stimulation or inhibition of designated sequence elements by the 
indicated agents. (B) Sequence of UPS DNA. The binding sites of octamer and AP-l-Iike factors are boxed. The consensus sequences for the 
binding of octamer and AP-I factors are written above the sequence, and the UPS nucleotides which match these sequences are underlined. 
The exact localization of factor-binding sites was determined in EMSA experiments with deletion and point mutations of UPS DNA (33). 
through cesium chloride gradients as described before (38). 
For the Sp6 protection mapping of IL-2 RNA, an anti sense 
Sp6 riboprobe of construct pGemII-E4R spanning exon 4 
and part of exon 3 of the murine chromosomal IL-2 gene (44) 
was hybridized to whole RNA from El4 cells as described 
previously (42). After RNase treatment, the protected RNA 
probe was fractionated on a 5% polyacrylamide sequencing 
gel. 
RESULTS AND DISCUSSION 
In order to study the effect of TGF-f3 on the inducible, 
T-Iymphocyte-specific transcription of the IL-2 gene, we 
initially investigated the effect ofTGF-f3 on the accumulation 
of endogenous IL-2 RNA in El4 T lymphoma cells. EI4 T 
cells synthesize and secrete large amounts of IL-2 after 
induction by the phorbol ester TPA or, to a greater extent, 
by TP A and a plant lectin, such as ConA. No IL-2 is 
synthesized in unstimulated EI4 cells. This implies that 
important regulatory mechanisms controlling the correct 
transcription of the IL-2 gene are intact in these cells. 
Sp6 RNase protection mapping of endogenous IL-2 RNA 
generated upon induction of EI4 ceUs shows that the accu-
mulation of mature cytoplasmic IL-2 RNA is efficiently 
blocked by low doses of TGF-f3 (2.5 ng/ml). The same effect 
was observed for CsA (Fig. 1). This suggests that TGF-f3, 
like CsA (35), intederes with the transcriptional control of 
the murine IL-2 gene. In order to test this assumption, we 
studied the effect of TGF-~ on the activity of the IL-2 
enhancer in transient-transfection assays. As expected, 
treatment of El4 cells with TGF-f3 for 15 h led to a decrease 
in IL-2 enhancer-directed CAT activity to about one-third of 
the normal level (see Fig. 3A). 
The murine IL-2 enhancer harbors numerous binding sites 
for protein factors and several proto-enhancer elements (Fig. 
2A). The latter are binding sites for positive-acting trans-
acting factors. When these sites are cloned in multiple copies 
in front of an indicator gene, they exhibit an inducible, 
T-cell-restricted activity like that of the entire IL-2 enhancer 
(4, 5, 35, 42). Previously, we and others showed that CsA 
and FK506 selectively inhibit the activity of purine boxes, 
the binding site ofthe lymphoid-specific factor NFAT-1, and 
of the UPS (4, 10,35) when they are added to the cells at the 
same time as (or after) the inducers. The activity of other 
sites, such as the KB-Iike TCEd motif (5) or art AP-1 binding 
site, was not or only marginally affected by both drugs under 
the same conditions (4). The selective effect of CsA on the 
IL-2 enhancer sites (and factors) prompted us to investigate 
the effect of TGF-f3 on these sites in transient-transfection 
experiments. 
The results of these experiments, shown in Fig. 3A, 
indicate that in El4 T cells, TGF-f3 quite selectively inter-
feres with the inducible activity of the UPS motif. Similar to 
its inhibitory effect on the entire IL-2 enhancer, TGF-f3 
treatment of EI4 cells resulted in a significant decrease in 
UPS-directed CAT activity, to about 20% of the normal 
level. TGF-f3 did not exert any negative effect on the activity 
of (KB-like) factors binding to the TCEd motif, and in 
contrast to the result with CsA, the activity of Pu-bd , a 
binding site of NF AT-I, was only weakly affected. Similarly, 
TGF-f3 did not inhibit the activity of AP-l, since the induc-
ible activity of a 5 x TREcoll construct remained unaffected 
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FIG. 3. TGF-p and CsA suppress the inducible activity of the IL-2 enhancer and of octamer-binding sites in T lymphoma cells. (A) The 
effect of TGF-p and CsA on the inducible activity of the IL-2 enhancer-CAT construct pILCA TI/1 + (WT -E), the IL-2 proto-enhancer-CAT 
plasmids 5 x UPS,S x TCEd, and 4 x Pu-bd , and the CAT constructs 5 x TREcoll, carrying five copies of an AP-1 consensus site (2), and 4 x Oct, 
containing four copies of a 50-bp IgH enhancer fragment with its octamer consensus site (15). Plasmid DNAs (20 ILg) were transfected into 
about 5 x 107 El4 cells by the DEAE-dextran method. After 20 h, the cells were divided. One-fourth of the cells were incubated for 16 h with 
TGF-p (2.5 ng/ml) (hatched columns), and one-fourth were incubated for 16 h with CsA (100 lLg/ml) (stippled columns); both treatments were 
followed by induction with TP A/ConA for 20 h in the presence of inhibitors. Control cell cultures were either induced for 20 h with TP A/ConA 
(solid columns) or uninduced (not shown). Shown are the mean values for at least three (for 5xUPS, five) independent transfection 
experiments. (B) Transactivation of the 5 x UPS construct by overexpressing Oct-2A in human Jurkat T lymphoma cells is impaired by TGF-p. 
DNA from 5xUPS (2.5 ILg) and 5 ILg of the Oct-2Aexpression vector pOEV1+ (31) were cotransfected into Jurkat cells by the DEAE-dextran 
method. One-fifth of the cells was used as an uninduced control, in which no Oct cDNA was cotransfected (not shown); the other aliquots 
were not cotransfected but were induced with TPA/ConA (open column) cotransfected and induced in the absence (solid column) or presence 
of Oct-2 plus TGF-p (hatched column) or CsA (stippled column). The cells were treated and further processed as described for panel A. (C) 
TGF-p and CsA impair the inducible activity of octamer factors in El4 cells. Luciferase reporter constructs containing eight copies of either 
the octamer consensus sequence ATGCAAAT (8xOct-Iucif) or the mutated version ATGAAAAT (8 x Oct-M-lucif) were transfected into El4 
cells, which were treated as described for panel A. After incubation of the cells, extracts were prepared and analyzed for luciferase activity 
as described before (9). (D) The activity of the murine IgH enhancer is suppressed by TGF-p but not by CsA in A20J B lymphoma cells. An 
IgH enhancer-CAT construct (containing the intronic XbaI-E fragment of the IgH gene [3]) was transfected into A20J cells. The cells were 
divided into four portions, and TGF-p (2.5 ng/ml) or CsA (100 ng/ml) was added to two portions. After 16 h, lipopolysaccharide (10 lLg/ml) 
and TPA (50 ng/ml) were added to the treated cells and to one portion of untreated cells (solid columns), while the remaining fourth was used 
as an un induced control. After further incubation for 20 h, the cells were harvested and the CAT activities were determined. In uninduced 
cells, the IgH enhancer construct showed a constitutive CAT activity of approximately 10%. Shown are the mean values of three independent 
transfection experiments. 
by TGF-~, while that of an IL-2 enhancer construct (desig-
nated 152C-enhancer), containing a defect mutation within 
the TREp at its major binding site for genuine AP-l (32), 
appeared to be inhibited, as the wild-type enhancer was (Fig. 
3A and 4). 
In DNase I footprint protection experiments with protein 
extracts from induced El4 cells or HeLa cells, about 30 bp of 
UPS DNA was found to be protected against DNase I 
cleavage (42). When this sequence was used as a radioactive 
probe in EMSAs, three specific, prominent DNA-protein 
complexes were formed after incubation with crude nuclear 
extracts from induced and uninduced E14 lymphoma cells 
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FIG. 4. Mutations within the UPS site which suppress factor 
binding render the inducible activity of the IL-2 enhancer resistant 
to TGF-~, while a defect mutation at the TREp site has no influence 
on the TGF-~ effect. IL-2-CAT constructs containing the IL-2 
wild-type enhancer (WT-E), the UPSn. enhancer (UPSn.-E) con-
taining a defective UPS AP-1 site, the UPSOM enhancer (UPSoM-E) 
containing a defective UPS Dct site, the UPSQThf enhancer 
(UPSoTM-E) containing both mutations in the UPS DNA, and the 
152C-enhancer (152C-E) containing a defect mutation within the 
TREp were transfected into EI4 cells as described in the legend to 
Fig. 3 and Materials and Methods. The cells were divided into four 
portions; one-fourth were incubated for 16 h with TGF-~ (2.5 ng/ml), 
and one-fourth were incubated for 16 h with CsA (100 ng/ml); both 
treatments were followed by induction with TPAlConA for 20 h in 
the presence of inhibitors. The other two portions were either 
induced for 20 h with TPAlConA (solid columns) or used as an 
uninduced control (not shown). The CAT activities were determined 
as described in the text. Shown are the mean values of three 
independent transfection experiments. 
(Fig. SA, lanes 1 to S). Since identical complexes were also 
generated when a radioactive probe of the IgH enhancer 
carrying an octamer consensus sequence was used (Fig. SA, 
lanes 6 to 8) and the formation of all three complexes could 
be inhibited by an excess of authentic octamer DNA (Fig. 
5A, lane 4) but not by the same excess of an unrelated 
oligonucleotide (not shown), the formation of the three 
complexes must be due to the binding of octamer factors, 
probably the ubiquitous factor Oct-l and the lymphoid-
specific factors Oct-2A and Oct-2B (40). This conclusion is in 
line with published data on the binding of octamer factors to 
the same site of the human IL-2 enhancer (18) and is 
supported by our observation that the generation of Oct-l 
and Oct-2 complexes can be suppressed by preincubation of 
nuclear extracts with antibodies directed against the octamer 
proteins Oct-l and Oct-2 (33). 
However, octamer factors are not the only DNA-binding 
proteins which interact with the UPS DNA. In a previous 
publication, we have described the binding of purified AP-l 
(and AP-3) to UPS DNA in DNase I footprint protection 
experiments (42), and Ullman et al. have reported the 
binding of a so-called octamer-associated protein, oAP'"', to 
the same site of the human IL-2 enhancer (45). In EMSA 
experiments with UPS DNA as the probe and a lOO-fold 
molar excess of authentic octamer DNA as the competitor, 
we observed one specific factor complex, the formation of 
which was not inhibited in the presence of the octamer DNA 
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(Fig. 5B, lane 2). The generation of this complex can be 
inhibited by a lOO-fold molar excess of TREcoll DNA (or 
another canonical AP-l binding site) but not by the same 
excess of TCEd or Pu-bd DNA (Fig. 5B, lanes 4 to 6). 
Moreover, incubation of UPS or TREcoll probes with bac-
terially expressed v-Jun resulted in the generation of identi-
cal factor complexes (Fig. 5B, lanes 7 to 10). This shows that 
AP-l-like factors are able to interact with UPS DNA se-
quences. Accordi~g to all experimental data, they corre-
spond to the O~ factor described recently (4S). We will 
descripe elsewhere our finding that AP-l-Iike factors interact 
with the sequence TGTGTAA, which is closely linked to the 
octamer-like binding sequence ATGTAAAA and shares five 
out of seven nucleotides with a canonical AP-l binding 
sequence (Fig. 2B) (33). This site was described as the 
binding site of oAP'"' in the human IL-2 enhancer (45). 
The close linkage of binding sites for octamer and AP-I-
like factors within the UPS DNA and the resistance to 
TGF-~ of SxTREcoll plasmids containing five AP-l binding 
sites (Fig. 3A) prompted us to investigate whether the 
activity of an authentic octamer site is also affected by 
TGF-~ and CsA. As the test plasmid, we initially used a 
tetrameric octamer-CAT plasmid bearing four copies of a 
SO-bp-long DdeI-HinfI fragment from the murine IgH en-
hancer. This fragment has frequently been used for studying 
the binding and activity of octamer factors because its most 
prominent factor-binding site corresponds to a canonical 
octamer sequence (IS). Like the activity of the S x UPS-CAT 
construct, the activity of the 4xOct-CAT plasmid was 
impaired by TGF-~ after transfection into El4 cells (Fig. 3A). 
However, in addition to the octamer motif, the DdeI-HinfI 
fragment harbors further potential transcriptional factor-
binding sites, like the ~E4 motif (11) and the TRE half-site 
TGAC. 
To show directly that the octamer motif is a target of 
TGF-~ repression and to rule out any contribution of these 
additional sites, we next tested reporter constructs that 
carried eight copies of either a synthetic wild-type or mutant 
octamer oligonucleotide upstream of a TAT A box. The 
results of these transfection experiments are shown in Fig. 
3C and indicate that the activity of canonical octamer sites is 
also impaired by TGF-~, although not as efficient as that of 
UPS DNA (about 40 versus 20% inhibition: compare Fig. 3C 
and 3A). Moreover, TGF-~ is also able to impair the activity 
of the IgH enhancer in B lymphoma cells (Fig. 3D). Since 
this has also been detected for the 4 x Oct construct contain-
ing the IgH enhancer's octamer site (unpublished result), the 
TGF-~ effect in B cells might also be mediated through 
octamer factors. In contrast, CsA has no inhibitory effect on 
the IgH enhancer (Fig. 3D) and octamer factors in B cells 
(not shown). 
In order to test whether the UPS site is the only target for 
TGF-~ within the IL-2 enhancer, we introduced into the 
enhancer three UPS mutations which suppressed the binding 
of either octamer factors (UPSOM)' AP-l (UPSnt), or both 
factors (UPSOTM) (33). When these IL-2-CAT constructs 
were transfected into El4 cells and tested in the presence of 
TGF-~ (or CsA), their reduced inducible activity appeared to 
be completely resistant to TGF-~ but not to CsA (Fig. 4). In 
contrast, a defect mutation of the TREp site at the enhanc-
er's major site for the binding of genuine AP-l did not lead to 
a loss of the TGF-~ effect (Fig. 4). This indicates that the 
UPS element is the most important site for mediating the 
TGF-~ effect, whereas CsA acts through the two NFAT-l 
binding sites as well. 
In cotransfection studies with the S x UPS-CAT reporter 
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construct and cDNA vectors that overexpress octamer and 
Jun/Fos proteins, we have observed a distinct functional 
synergism of these factors in their action through the UPS 
(33). This has also been detected for the inhibitory effect of 
CsA on UPS activity (33) and might explain why the activity 
of the UP~ enhancer containing a defective UPS AP-l site 
but intact UPS octamer site remained unaffected by TGF-~ 
(Fig. 4). Experiments are in progress to elucidate how this 
synergism ("cross-talk") between octamer and AP-l-like 
factors might occur at the molecular level. 
Although TGF-~ inhibits the proto-enhancer activity of 
the UPS motif, it does not interfere with the factors binding 
to the UPS probe (Fig. SC). In this respect, TGF-~ acts like 
CsA, which also interferes with the activity but not with the 
binding of factors to UPS DNA (4,10). However, in striking 
contrast to CsA, TGF-~ does not have any negative influ-
ence on the binding of NFAT-l to the purine box (Fig. SC, 
lanes 17 to 20), nor did we detect any inhibitory effect of 
TGF-~ on the binding of AP-l to the TREp (unpublished 
results) or, as shown in Fig. SC (lanes 9 to 12), to the 
TREcoll. Frequently, we observed a distinct stimulation of 
binding of factors to the KB-like TCEd element (Fig. SC, 
lanes 13 to 16) or to authentic NF-KB binding sites (not 
shown). Taken together with the divergent effects of TGF-~ 
and CsA on the IgH enhancer in B cells (Fig. 3D), these data 
show that these drugs differ in their action on cellular signal 
transduction pathways. 
How does TGF-~ interfere with the activity (but not with 
the DNA binding) of octamer factors? It is now widely 
accepted that the suppression of c-myc gene expression is 
one of the key events in the growth-inhibitory response to 
TGF-~ (28, 30). The suppression of c-myc gene expression 
occurs at the transcriptional level (34). One likely candidate 
for mediating the inhibitory effect of TGF-~ on the c-myc 
promoter is pRB, the protein product of the growth-suppres-
sive retinoblastoma gene. The activity of pRB during the cell 
cycle is strictly regulated at the level of protein phosphory-
lation: pRB was found to be underphosphorylated in the G1 
phase and hyperphosphorylated in the Sand G2 phases (6, 
8). The phosphorylation of pRB in the late G1 phase was 
found to be sensitive to TGF-~ (24). Several studies showed 
that the activity of octamer factor Oct-l is also modulated in 
a cell cycle-dependent manner (13, 23), and, like pRB, Oct-l 
seems to represent a general target for the activity of cell 
cycle-dependent protein kinases. In a recent study on the 
phosphorylation of Oct-l in HeLa cells, Roberts et al. (37) 
detected distinct differences in the phosphorylation pattern 
of Oct-l during different phases of the cell cycle. One of the 
protein kinases involved in Oct-l phosphorylation is a 
p34cdc2_like kinase (37) which, in another system, was found 
to be inhibited by TGF-~ (17). Thus, it is tempting to 
speculate that in T lymphocytes, TGF-~ impairs the tran-
scription of the IL-2 gene by affecting the phosphorylation of 
octamer factors that bind to the UPS motif of the IL-2 
promoter through a block of cdc2-mediated phosphoryla-
tion. 
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